Number of Patients with Influenza and COVID-19 Coinfection in a Single Japanese Hospital during the First Wave

Kawai, Shoko; Fukushima, Kazuaki; Yomota, Makiko; Fukuda, Akito; Fujiwara, Sho; Tanaka, Masaru; Kobayashi, Taiichiro; Yajima, Keishiro; Hosomi, Yukio; Imamura, Akifumi

doi:10.7883/yoken.jjid.2020.1009

Cited by 10 publications

(10 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, although our study population was systematically tested for both viruses, no co-infection has been found in our cohort. This is consistent with the results of other studies assessing the incidence of SARS-CoV-2 and Influenza co-infections which was very low, ranging from zero to 0.3% [29,30].…”

Section: Discussionsupporting

confidence: 92%

“…There was no difference in neurological medical history. At admission, patients with Covid-19 were less severe than patients with influenza (SAPS II score 33 [24][25][26][27][28][29][30][31][32][33][34][35][36][37][38][39][40][41][42] vs. 46 , p < 0.001). There was no significant difference in the cumulative doses of sedation between the 2 groups, except for the propofol (6938 mg [1694-16375] vs. 3400 mg [1050-7550], p = 0.011).…”

Section: Unmatched Populationmentioning

confidence: 99%

See 1 more Smart Citation

Acquired agitation in acute respiratory distress syndrome with COVID-19 compared to influenza patients: a propensity score matching observational study

Maamar

Liard

Doucet

et al. 2022

Virol J

View full text Add to dashboard Cite

Background A growing body of evidence reports that agitation and encephalopathy are frequent in critically ill Covid-19 patients. We aimed to assess agitation’s incidence and risk factors in critically ill ARDS patients with Covid-19. For that purpose, we compared SARS-CoV-2 acute respiratory distress syndrome (ARDS) patients with a population of influenza ARDS patients, given that the influenza virus is also known for its neurotropism and ability to induce encephalopathy. Methods We included all the patients with laboratory-confirmed Covid-19 infection and ARDS admitted to our medical intensive care unit (ICU) between March 10th, 2020 and April 16th, 2021, and all the patients with laboratory-confirmed influenza infection and ARDS admitted to our ICU between April 10th, 2006 and February 8th, 2020. Clinical and biological data were prospectively collected and retrospectively analyzed. We also recorded previously known factors associated with agitation (ICU length of stay, length of invasive ventilation, SOFA score and SAPS II at admission, sedative and opioids consumption, time to defecation). Agitation was defined as a day with Richmond Agitation Sedation Scale greater than 0 after exclusion of other causes of delirium and pain. We compared the prevalence of agitation among Covid-19 patients during their ICU stay and in those with influenza patients. Results We included 241 patients (median age 62 years [53–70], 158 males (65.5%)), including 146 patients with Covid-19 and 95 patients with Influenza. One hundred eleven (46.1%) patients had agitation during their ICU stay. Patients with Covid-19 had significantly more agitation than patients with influenza (respectively 80 patients (54.8%) and 31 patients (32.6%), p < 0.01). After matching with a propensity score, Covid-19 patients remained more agitated than influenza patients (49 (51.6% vs 32 (33.7%), p = 0.006). Agitation remained independently associated with mortality after adjustment for other factors (HR = 1.85, 95% CI 1.37–2.49, p < 0.001). Conclusion Agitation in ARDS Covid-19 patients was more frequent than in ARDS influenza patients and was not associated with common risk factors, such as severity of illness or sedation. Systemic hyperinflammation might be responsible for these neurological manifestations, but there is no specific management to our knowledge.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Unmatched Populationmentioning

confidence: 99%

Acquired agitation in acute respiratory distress syndrome with COVID-19 compared to influenza patients: a propensity score matching observational study

Maamar

Liard

Doucet

et al. 2022

Virol J

View full text Add to dashboard Cite

show abstract

“… 1 , 2 As many countries decrease the use of such measures, 2 we expect that SARS-CoV-2 will circulate with other respiratory viruses, increasing the probability of co-infections. 1 , 3 The clinical outcome of respiratory viral co-infections with SARS-CoV-2 is unknown.…”

mentioning

confidence: 99%

SARS-CoV-2 co-infection with influenza viruses, respiratory syncytial virus, or adenoviruses

et al. 2022

View full text Add to dashboard Cite

“…There have been reports of co-infection with COVID-19 and seasonal influenza. Co-infection with these two diseases must be treated more carefully because they can cause increased suffering and mortality. − Although efforts for reducing the spread of COVID-19 have temporarily reduced the transmission of respiratory viruses simultaneously , and as these efforts are reduced gradually, the possibility of co-infection with COVID-19 and other seasonal influenzas may increase. , Therefore, developing a simultaneous detection test system for multiple infectious disease diagnoses is key to identifying the virus that causes symptoms and applying appropriate treatment.…”

Section: Introductionmentioning

confidence: 99%

Simultaneous Detection of Infectious Diseases Using Aptamer-Conjugated Gold Nanoparticles in the Lateral Flow Immunoassay-Based Signal Amplification Platform

Kim,

Baek,

Nam

et al. 2024

Anal. Chem.

View full text Add to dashboard Cite

Various platforms for the accurate diagnosis of infectious diseases have been studied because of the emergence of coronavirus disease (COVID-19) in 2019. Recently, it has become difficult to distinguish viruses with similar symptoms due to the continuous mutation of viruses, and there is an increasing need for a diagnostic method to detect them simultaneously. Therefore, we developed a paper-based rapid antigen diagnostic test using DNA aptamers for the simultaneous detection of influenza A, influenza B, and COVID-19. Aptamers specific for each target viral antigen were selected and attached to AuNPs for application in a rapid antigen diagnosis kit using our company's heterogeneous sandwichtype aptamer screening method (H-SELEX). We confirmed that the three viruses could be detected on the same membrane without cross-reactivity based on the high stability, specificity, and binding affinity of the selected aptamers. Further, the limit of detection was 2.89 pg•mL −1 when applied to develop signal amplification technology; each virus antigen was detected successfully in diluted nasopharyngeal samples. We believe that the developed simultaneous diagnostic kit, based on such high accuracy, can distinguish various infectious diseases, thereby increasing the therapeutic effect and contributing to the clinical field.

show abstract

Number of Patients with Influenza and COVID-19 Coinfection in a Single Japanese Hospital during the First Wave

Cited by 10 publications

References 10 publications

Acquired agitation in acute respiratory distress syndrome with COVID-19 compared to influenza patients: a propensity score matching observational study

Acquired agitation in acute respiratory distress syndrome with COVID-19 compared to influenza patients: a propensity score matching observational study

SARS-CoV-2 co-infection with influenza viruses, respiratory syncytial virus, or adenoviruses

Simultaneous Detection of Infectious Diseases Using Aptamer-Conjugated Gold Nanoparticles in the Lateral Flow Immunoassay-Based Signal Amplification Platform

Contact Info

Product

Resources

About